Two pre-clinical trials based on MEAI exhibited a significant suppressive effect on alcohol consumption in mice
TORONTO, March 17, 2022 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF, FSE: CWY0) (“Clearmind” or the “Company”) today announced promising results from two pre-clinical trials which tested suppression of alcohol consumption in mice using its novel psychedelic-based therapeutic CMND-100, whose active pharmaceutical ingredient is MEAI.
The first trial examined the effect of CMND-100 in several doses as a monotherapy. The second, done in collaboration with SciSparc Ltd. (NASDAQ: SPRC), examined the synergetic effect of combining lower concentrations of CMND-100 with SciSparc’s CannAmide™ (proprietary formulation of Palmitoylethanolamide or PEA) .
“We are excited to reveal that our proprietary CMND-100 showed very positive results that suggest strong potential for treating alcohol use disorder,” said Dr. Adi Zuloff-Shani, PhD, the CEO of Clearmind, which focuses on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems.
As part of the trials, the mice were provided with a 20% alcohol solution for 24 hours, three times a week for 7 weeks – and treated with MEAI daily during the last two weeks. The mice had free access to water to test their alcohol preference over water. Alcohol consumption was measured by weighing the alcohol bottles before and after. CMND-100 at doses of 40 mg/kg and higher demonstrated significant suppressive effect on alcohol consumption, reducing the alcohol consumed significantly lower than untreated controls (p<0.01).
The second trial aimed to test the hypothesis that sub-effective doses of CMND-100 in combination with CannAmide will further attenuate alcohol consumption (PEA is known as a safe neuro-potentiator). Results showed a significant reduction in alcohol consumption at the lower sub-effective MEAI dose when combined with CannAmide.
“CMND-100 showed very positive results both in our own target dose and in lower doses combined with SciSparc’s CannAmide™,” Zuloff-Shani said. “These results are a proof of concept for our goal of developing innovative, effective, and safe psychedelic treatments that could revolutionize the mental health market
About Clearmind Medicine Inc.
Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The company’s intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on the Canadian Securities Exchange under the symbol “CMND”, the Frankfurt Stock Exchange under the symbol “CWYO” and on the OTC pink under the symbol “CMNDF”.
About SciSparc (NASDAQ:SPRC):
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. Our focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol (CBD): SCI-110 for the treatment of Tourette syndrome, for the treatment of obstructive sleep apnea and Alzheimer’s disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and status epilepticus.
For further information, please contact:
FORWARD-LOOKING STATEMENTS: [Daniel to revise per Canadian requirements]
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such statements include submission of the relevant documentation within the required timeframe to the satisfaction of the relevant regulators and raising sufficient financing to complete the Company’s business strategy. There is no certainty that any of these events will occur. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.
Investing into early-stage companies inherently carries a high degree of risk, and investment into securities of the Company shall be considered highly speculative.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any province in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under the Private Placement have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
The content is by GlobeNewswire. DKODING Media is not responsible for the content provided or any links related to this content. DKODING Media is not responsible for the correctness, topicality or the quality of the content.